Lipoprotein-Associated Phospholipase A2 (Lp-PLA2): A Novel and Promising Biomarker for Cardiovascular Risks Assessment
Atherosclerosis and its manifestations namely cardiovascular diseases (CVD) are still the leading cause of morbidity and mortality worldwide. Although intensified interventions have been applied, the residual cardiovascular (CV) risks are still very high. Lipoprotein-associated phospholipase A2 (Lp-...
Main Authors: | Anping Cai, Dongdan Zheng, Ruofeng Qiu, Weiyi Mai, Yingling Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2013-01-01
|
Series: | Disease Markers |
Online Access: | http://dx.doi.org/10.3233/DMA-130976 |
Similar Items
-
Lipoprotein-associated phospholipase A2 (Lp-PLA2) in acute coronary syndrome
by: Jabor, Bashar
Published: (2016) -
Lipoprotein-associated phospholipase A2 (Lp-PLA2) – possible diagnostic and risk biomarker in chronic ischaemic heart disease
by: Adriana Diaconu, et al.
Published: (2021-01-01) -
Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment
by: Anping Cai, et al.
Published: (2013-01-01) -
Distribution of Paraoxonase-1 (PON-1) and Lipoprotein Phospholipase A2 (Lp-PLA2) across Lipoprotein Subclasses in Subjects with Type 2 Diabetes
by: Angelina Passaro, et al.
Published: (2018-01-01) -
Assessing associations of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) with coronary heart disease risk
by: Thompson, Alexander John
Published: (2009)